AbbVie Announces New UK Vice President and General Manager
For UK trade and national media
- Steve Hopkinson has been appointed UK Vice President and General Manager with effect from 1st August 2024
- An internal appointment, Steve takes on the position having held senior UK, European and Global commercial roles in his ten-year career at AbbVie
- Steve succeeds Todd Manning, who was appointed in 2019
Maidenhead, UK, 16 July, 2024 – AbbVie (NYSE: ABBV) AbbVie today announced that Steve Hopkinson has been appointed as Vice President and General Manager, UK. With effect from 1st August 2024, Steve will succeed Todd Manning, who retires from AbbVie after 28 years, the last five of which have been in the UK Vice President and General Manager role.
Steve joined AbbVie in 2014 as UK Specialty Business Unit Director. He went on to lead AbbVie’s Immunology franchise in the UK and across Western Europe and Canada before taking on a General Manager role in the company’s Global Marketing and Commercial operations team. He was promoted to his most recent position of European Area Commercial Head in 2022.
Commenting on his appointment, Steve said “It is a privilege to take on this role at such a pivotal time for AbbVie. Thanks to Todd’s leadership our UK business and culture are strong, and we are well placed to bring the innovations from our robust pipeline to UK patients. I look forward to building on Todd’s achievements and working with stakeholders across the UK life sciences community, Govt and NHS to ensure the value of innovative medicines can be realised by the wider healthcare system.”
Prior to joining AbbVie, Steve worked at Otsuka Pharmaceuticals as European Digital Health and Access Director and at Lundbeck, where he was Head of Psychiatry.
Steve holds a Bachelor of Science Degree in Biology and Sports Medicine from University of Chester, England.
-ENDS-
NOTES TO EDITORS
Picture
A picture of Steve Hopkinson is available on request.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at abbvie.co.uk. Follow @abbvieuk on X, formerly known as Twitter, and YouTube (@abbvieuk6755).
UK-ABBV-240193 | July 2024
UK Media:
Natalie Bennett
+44 (0) 7977 678 377
Or
UK Media Relations
+44 (0) 1628 925200